- Home
- AFCG vs IBIO Comparison
AFCG vs IBIO Comparison
Compare AFCG & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFCG | IBIO |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.9M | 50.4M |
| IPO Year | 2020 | 2009 |
Fundamental Metrics
Financial Performance| Metric | AFCG | IBIO |
|---|---|---|
| Price | $2.59 | $2.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $5.75 | $4.75 |
| AVG Volume (30 Days) | 214.8K | ★ 1.1M |
| Earning Date | 06-03-2026 | 05-20-2026 |
| Dividend Yield | ★ 23.35% | N/A |
| EPS Growth | N/A | ★ 73.08 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,563,601.00 | N/A |
| Revenue This Year | $1,206.46 | N/A |
| Revenue Next Year | $15.39 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.06 | $0.56 |
| 52 Week High | $8.55 | $5.85 |
Technical Indicators
Market Signals| Indicator | AFCG | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 59.93 | 53.96 |
| Support Level | $2.52 | $2.02 |
| Resistance Level | $3.35 | $3.01 |
| Average True Range (ATR) | 0.13 | 0.24 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 76.32 | 45.83 |
Price Performance
Historical ComparisonAbout AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is a commercial mortgage REIT that provides institutional loans to cannabis operators in the U.S. Through the management team's deep network and related credit and cannabis expertise. The company originates, structures, and underwrites loans secured by quality real estate assets, license value, and cash flows.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.